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Background: Henoch-Schönlein purpura (HSP) primarily affects children, but age at 
onset is thought to be important in determining disease severity and outcome. This 
study compared the clinical and laboratory data from children and adults with HSP. 
Methods: This retrospective 5-year study enrolled 65 children and 22 adult HSP 
patients attending a medical center.
Results: Gross hematuria and lower-extremity edema were significantly more frequent 
in adults (p < 0.05). All the children developed renal involvement within 2 weeks, 
while 67% of the adult patients developed hematuria by the fifth week of disease 
onset. Elevated white blood cell count and increased erythrocyte sedimentation 
rate were significantly more common in children (p < 0.05). Adults had a higher fre-
quency of renal involvement (p < 0.05), though this was also present in 14 children 
(21.54%), 12 with isolated hematuria and proteinuria and two with nephrotic syn-
drome. All the children maintained normal renal function. Twelve adults had renal 
involvement (52.6%), six with progression to renal insufficiency. Patients with abdom-
inal pain at disease onset had a significantly higher probability of developing neph-
rotic syndrome (p < 0.05). Logistic regression revealed that age > 20 years, male, 
bloody stools, clinical course with relapse of purpuric rash, and persistent rash for 
> 1 month were poor prognostic indicators for HSP nephritis (p < 0.05). 
Conclusions: HSP nephritis in adults had a higher risk of progression to renal insuffi-
ciency. More aggressive treatment and extended follow-up with repeated urinalysis 
for at least 6 weeks were often necessary, especially in older patients.
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1. Introduction
Henoch-Schönlein purpura (HSP) is a non-thrombocy-
topenic systemic vasculitis of childhood, character-
ized by small-vessel leukocytoclastic vasculitis with 
the deposition of immune complexes containing IgA. 
The clinical features include a palpable purpuric 
rash, arthralgia, gastrointestinal (GI) involvement 
(with abdominal pain and/or gastrointestinal bleed-
ing), and renal involvement. The etiology is unknown. 
The prognosis generally is good, except for cases 
with renal involvement.1
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HSP has a peak incidence in the first and sec-
ond decades of life, with a male predominance.2,3 
The annual incidence in children is estimated to 
be 14 cases per 100,000.4 The incidence in adults, 
however, is only 1.3 per 100,000, with a mean age 
at presentation of about 50 years.2 In childhood 
HSP, the male:female ratio ranges from 1.2−1.6.5 
However, in adults, males and females are equally 
affected.2 
The age at onset has been considered to be an 
important factor in determining disease manifes-
tation, severity and outcome.6,7 However, the inci-
dence of renal involvement is higher in older patients. 
Renal involvement has been reported to occur in 
30−40% of children and up to 45−85% of adult 
patients.5,8 Most recent studies have focused on 
childhood HSP; there has been a relative paucity 
of studies on adult patients. The purpose of this 
study was to compare the differences in epidemi-
ology, clinical parameters, laboratory data, and out-
comes between children and adults with HSP in 
Taiwan, and to analyze the factors associated with 
poor prognosis for HSP nephritis.
2. Materials and Methods
This retrospective study enrolled cases between 
January 2000 and December 2005 at the National 
Taiwan University Hospital. The patients were di-
vided into two groups based on the age at disease 
onset. We designated “childhood HSP” as disease 
onset prior to 20 years of age, and patients with 
later onset were classified as “adult HSP”. Patients 
with a clinical diagnosis of HSP were identified from 
medical records, and had to fulfill the criteria for 
the diagnosis of HSP established by the American 
College of Rheumatology (ACR 1990). This diagno-
sis required individuals to have two or more of four 
criteria: age < 20 years at disease onset, palpable 
purpura, acute abdominal pain or gastrointestinal 
bleeding, and a biopsy showing granulocytes in the 
walls of small arterioles or veins.9 The diagnosis of 
HSP, according to these criteria, may yield a sensi-
tivity of 87.1% and a specificity of 87.7%. The adult 
patients were confirmed by skin biopsy showing 
leukocytoclastic vasculitis. All patients had been 
followed up at the outpatient department for at 
least 12 months. We excluded patients with throm-
bocytopenia (platelet count < 100,000/mm3) and 
cases that did not fulfill the ACR criteria.
The patient charts were reviewed and the data 
collected included clinical symptoms, laboratory 
data and treatment courses. Renal involvement 
classified into two categories: (1) isolated micro-
scopic hematuria and/or proteinuria (IHP) was de-
fined as > five red blood cells per high-power field 
on the sediment from 10 mL of centrifuged, freshly 
voided urine, or a small amount of proteinuria 
(> 30 mg/dL) on dipstick testing, or proteinuria in 
urine collected for 24 hours (0.1−3 g/24 hours in 
adults, or 4−40 mg/m2/h for children); (2) nephrotic 
syndrome (NS) was defined as proteinuria mea-
sured in a 24-hour urine collection demonstrating a 
protein content of > 3.5 g in adults or > 40 mg/m2/h 
or 50 mg/kg/24 hours in children, and hypoalbu-
minemia (serum albumin < 2.5 g/dL), with or with-
out edema, and hyperlipidemia. Renal insufficiency 
(RI) was defined as a plasma creatinine concentra-
tion > 1.2 mg/dL.1
Data are presented as mean ± standard devia-
tion (SD) for continuous data and categorical vari-
ables are presented as percentages. Comparisons 
were performed using Student’s t-test for continu-
ous variables. We analyzed categorical data using 
χ2 test or Fisher’s exact test when the minimum 
expected value was < 5. We evaluated the poten-
tial prognostic factors for HSP nephritis using a lo-
gistic regression model. p < 0.05 was considered to 
be statistically significant. Statistical analysis was 
performed using SAS 8.2 software (SAS Institute, 
Cary, NC).
3. Results
3.1.  Epidemiology of HSP in children and 
adults
We enrolled 87 patients. Sixty-five patients were 
assigned to the “childhood HSP” group (35 male 
and 30 female), and 22 patients were assigned to the 
“adult HSP” group (11 male and 11 female). A male 
predominance was noted in our study, with a 
male:female ratio of 1.17:1 in the childhood HSP 
group, but a 1:1 ratio in the adult group. The age at 
disease onset ranged from 2.5−88 years. The mean 
age at disease onset was 6.89 ± 3.69 years in the 
childhood group and 43.5 ± 18.61 years in the adult 
group. 
3.2.  Comparison of clinical manifestations 
and laboratory findings of HSP 
between children and adults
The frequency of upper respiratory tract infections 
occurring within 1 week prior to the onset of symp-
toms of HSP in the childhood group was 47.7%, vs. 
36.4% in adults. In contrast, the adult group dem-
onstrated a more frequent history of medication 
use prior to the onset of HSP (10.5% vs. 3.6%), but 
this difference was not significant.
The main clinical features are summarized in 
Figure 1. All the patients in both groups presented 
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with palpable purpura, and the purpuric rash also 
involved the trunk and upper extremities in about 
half the patients. Gross hematuria and lower-
extremity edema were more frequent in the adult 
group (p < 0.05). About one third of the children, 
but none of the adults, suffered from sinusitis 
(p < 0.05).
Patients in the childhood group more frequently 
presented with abdominal pain before the appear-
ance of purpuric rash (24.62% vs. 4.55%, p < 0.05). 
The interval between the onset of abdominal pain 
and purpuric rash could be as long as 21 days (range 
1−21 days; mean, 8.31 ± 5.52 days). All the patients 
in the childhood group developed hematuria within 
2 weeks (33% in the first week and 67% in the sec-
ond week), while this interval could be as long as 5 
weeks in adults (34% within 2 weeks and 67% pa-
tients by the fifth week). The frequencies of gross 
hematuria and lower-extremity edema were also 
significantly higher in adult patients than in chil-
dren (p < 0.05).
The major laboratory results at the onset of 
HSP are shown in Table 1. The frequency of elevated 
white blood count (WBC count > 11,000/mm3) was 
significantly higher in the pediatric group (53.85% 
vs. 27.27%, p < 0.05).
PURI
Sinusitis
Fever†
Purpura
RUT
RLE
PPR
Abd pain
Arthralgia or arthritis
Ghematuria
LE edema
Hypertension
Bloody stool
Frequency of manifestation (%)
*
*
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Figure 1 Clinical manifestations of Henoch-Schönlein purpura in children and adults. Higher frequency of lower-
extremity edema and gross hematuria were found in the adult group (p < 0.05). LE edema = lower extremity edema; 
Ghematuria = gross hematuria; Abd pain = abdominal pain; PPR = persistent purpuric rash for more than one month; 
RLE = rash distribution on lower extremities; RUT = rash distribution included upper extremities, trunk and lower 
extremities; PURI = upper respiratory tract infection within one month prior to disease onset. *p < 0.05. †Fever defined 
as body temperature > 38°C.
Table 1 Laboratory findings at the initial onset of Henoch-Schönlein purpura
 Children (n = 65) Adults (n = 22)
 No. of patients (%) No. of patients (%)
WBC > 11,000/mm3 35/65 (53.85)* 6/22 (27.27)
Platelet > 400,000/mm3 29/65 (44.62) 6/22 (27.27)
Hb < 10 g/dL 1/65 (1.5) 1/22 (4.5)
ESR > 20 mm/h  16/32 (50) 6/10 (60)
CRP > 1.0 mg/dL 19/46 (41.30) 10/18 (55.56)
C3 < 80 mg/dL  1/57 (1.75) 2/19 (10.53)
C4 < 15 mg/dL 14/56 (25) 2/19 (10.53)
IgA > 300 mg/dL 12/49 (24.49) 7/14 (50)
Positive ANA 7/46 (15.22) 5/19 (26.32)
ASO > 200 IU/mL 9/47 (19.15) 2/11 (18.18)
Positive GAS 6/22 (27.27) 0/3
Stool occult blood > 2+  11/55 (20) 3/10 (30)
*p < 0.05. WBC = white blood cell count; Hb = hemoglobin; ESR = erythrocyte sedimentation rate at first hour; CRP = C-reactive pro-
tein; C3 = complement 3; C4 = complement 4; IgA = serum immunoglobulin A; ANA = anti-nuclear antibody; ASO = anti-streptolysin 
O titer; GAS = throat swab bacteria culture found group A streptococcus.
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We also compared the laboratory data obtained 
during the acute and the resolution stages of HSP. 
The erythrocyte sedimentation rate (ESR) during 
the acute stage in children was significantly higher 
than that during the resolution stage (p < 0.05), but 
this was not the case in adult patients (Figure 2).
3.3.  Comparison of characteristics in 
patients with renal involvement
There were 14 patients (21.54%) with renal involve-
ment in the childhood group. Twelve of these pre-
sented with isolated hematuria and/or proteinuria, 
while only two patients had nephrotic syndrome. 
However, all the patients in the pediatric group had 
normal renal function. In contrast, twelve patients 
in the adult group (52.6%) presented with renal in-
volvement (p < 0.05). Six of these presented with 
IHP, while three additional patients had nephrotic 
syndrome in combination with renal insufficiency. 
Another three patients developed hematuria and 
proteinuria accompanied by renal insufficiency.
There were no significant differences between 
cases with and without renal involvement or neph-
rotic syndrome in terms of leukocytosis, throm-
bocytosis, increased ESR, low complement 3 or 
complement 4 levels, increased IgA concentrations, 
or increased anti-streptolysin O titer. However, older 
patients (> 20 years) had a significantly higher prob-
ability of developing renal involvement and nephrotic 
syndrome (p < 0.05). Patients with abdominal pain at 
the onset of disease activity had a significantly 
higher probability of developing nephrotic syn-
drome (p < 0.05) (Table 2).
Logistic regression analysis revealed that age > 20 
years, male gender, bloody stools, persistent rash 
(defined as purpuric rash persisting for more than 
1 month), and relapse of symptoms were poor 
prognostic indicators for HSP nephritis (p < 0.05) 
(Table 3).
3.4.  Treatment course for patients
with HSP
In this study, 49 pediatric cases (75.38%) received 
corticosteroid therapy, with a mean total dosage (as 
prednisolone equivalent dose) of 18.96 ± 26.13 mg/kg. 
The duration of therapy ranged from 1−326 days 
(mean, 26.30 days). In the adult group, 15 patients 
(65.22%) were treated with prednisolone at a mean 
dose of 14.00 ± 18.65 mg/kg for 4−552 days (mean, 
52.91 days). 
In cases with renal involvement, 14 patients 
(28.57%) in the pediatric group received cortico-
steroid treatment, with a mean dosage of 
37.26 ± 23.22 mg/kg. Ten patients (66.67%) in the 
adult group also received steroid treatment, with 
a mean dosage of 38.45 ± 61.91 mg/kg. There was 
no significant difference in dosages between the 
pediatric and adult groups. Patients with renal
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Figure 2 Comparison of the laboratory data for patients with Henoch-Schönlein purpura (HSP) between the acute 
and resolution stages of disease course. Laboratory data for (A) the childhood group and (B) the adult group. The 
erythrocyte sedimentation rates at the onset of HSP and during the resolution stage, defined as disappearance of 
purpuric rash, were significantly different in both groups. WBC = white blood count (1,000/mm3); Platelet count 
(100,000/mm3); ESR = erythrocyte sediment rate (mm in 1 hour); CRP = C reactive protein (mg/dL); C3 = complement 
3 (10 mg/dL); C4 = complement 4 (mg/dL). *p < 0.05.
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involvement were significantly more likely to
receive steroids (OR 6.3, 95% CI 1.36−29.27, 
p < 0.05). There was no difference between pa-
tients with and without renal involvement regard-
ing the time interval from occurrence of the 
purpuric rash to the start of corticosteroid treat-
ment. One pediatric patient and one adult patient 
received corticosteroid pulse therapy for renal in-
volvement with nephrotic syndrome. In addition, 
cyclophosphamide pulse therapy was given to one 
adult patient with renal insufficiency. 
3.5. Outcome
In the childhood group, nine patients (32.1%) re-
quired admission more than twice for HSP and/or its 
complications, and nine adults (26.3%) were read-
mitted. During their disease course, seven children 
Table 2  Comparison of the clinical and laboratory features of cases with renal involvement and nephrotic
syndrome
 Renal involvement (n = 26) Nephrotic syndrome (n = 5)
 Cases  % p value Cases  % p value
Adult 12 46.15 p < 0.05 3 60 p < 0.05
URI 9 34.62 NS 1 12.5 NS
Abdominal pain 21 80.77 NS 5 100 p < 0.05
GI bleeding 6 23.08 NS 0 0 NS
Arthralgia 18 69.23 NS 3 60 NS
Fever 11 42.31 NS 2 25 NS
Persistent rash 15 57.69 NS 4 80 NS
Maculo. rash 6 23.08 NS 0 0 NS
RLE 25 96.15 NS 0 0 NS
Leukocytosis* 14  53.89 NS 3 37.5 NS
Thrombocytosis† 9  34.62 NS 2 25 NS
ESR > 20 mm/h 10 71.43 NS 3 75 NS
C3 < 80 mg/dL 2 9.09 NS 1 14.29 NS
C4 < 15 mg/dL 3 13.64 NS 1 14.29 NS
IgA > 300 mg/dL 4 21.05 NS 2 40 NS
ASO > 200 IU/mL 3 11.54 NS 0 0 NS
*White blood cell count > 11,000/mm3. †Platelet count > 400,000/mm3. URI = upper respiratory tract infection; GI bleeding = gastro-
intestinal bleeding; Maculo. rash = maculopapular rash; RLE = rash distribution on lower extremities; ESR = erythrocyte sediment 
rate at first hour; C3 = complement 3; C4 = complement 4; IgA = serum immunoglobulin A; ASO = anti-streptolysin O titer; NS = 
not significant.
Table 3 Logistic regression analysis of poor prognostic factors for Henoch-Schönlein purpura nephritis
 Renal involvement (n = 26)
 OR 95% CI  OR 95% CI
Age > 20 yrs 11.95* 2.44−58.52 Leukocytosis† 1.47 0.58−3.69
Male 6.70* 1.23−36.46 Thrombocytosis‡ 0.71 0.27−1.85
Bstool 4.28* 1.09−16.72 Increased ESR 1.62 0.45−5.81
Relapse 14.4* 3.53−58.7 High CRP 1.33 0.47−3.75
Prash 2.60* 1.01−6.65 Increased IgA 0.52 0.151.83
RUT 1.54 0.61−3.89 C3 < 80 mg/dL 5.3 0.46−61.72
Abd pain 2.92 0.97−8.77 Increased ASO 0.73 0.17−3.12
URI 0.55 0.21−1.42 GAS positive 1.15 0.42−3.13
Sinusitis 0.73 0.23−2.27 Antibiotics 0.81 0.29−2.26
Arthralgia 1.36 0.51−3.63
*p < 0.05. †Leukocytosis = white blood cell count > 11,000/mm3. ‡Thrombocytosis = platelet count > 400,000/mm3. Bstool = bloody 
stool; Relapse = defined as symptoms recur after one month free of symptoms; Prash = persistent rash more than 4 weeks; RUT = 
rash distribution upon trunk; Abd pain = abdominal pain; URI = upper respiratory tract infection 7 days before the onset of HSP; 
ESR = erythrocyte sediment rate at first hour; High CRP = C-reactive protein > 1.0 mg/dL; Increase IgA = serum immunoglobulin A 
> 300 mg/dL; C3 = complement 3; Increase ASO = anti-streptolysin O titer > 200 IU/mL; GAS positive = throat swab bacteria culture 
found group A streptococcus; OR = odds ratio; CI = confidence interval.
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relapsed (defined as a flare up of disease after an 
interval of 1 symptom-free month) and five adult 
patients also relapsed. The mean intervals to re-
lapse in the two groups were 161 ± 141.2 days and 
72.25 ± 53.0 days, respectively (p = 0.12).
In cases with IHP, only two children and one 
adult still manifested persistent hematuria after 1 
year. In cases with nephrotic syndrome, one child 
underwent complete recovery and another child 
had persistent hematuria, but with normal renal 
function, at the latest follow-up (12 months). 
Three adults had persistent renal insufficiency de-
tected during the last follow-up (at least 14 months 
after disease onset).
4. Discussion
All of the patients with Henoch-Schönlein purpura in 
this study, as in previous studies,10−13 presented with 
purpuric rash, which was the most common initial 
symptom in both adult and pediatric patients. 
However, abdominal pain as the first presenting 
symptom was more frequent in children. None of 
the patients had nephritis prior to the onset of rash. 
The frequency of GI involvement was more com-
mon in children in this study, but García-Porrúa et al 
reported that GI manifestations were similar in both 
children and adults.7 However, almost one third of 
the pediatric patients in this study had symptoms 
and signs of sinusitis, and the purpuric rash improved 
after the sinusitis was controlled. This was the first 
study comparing this infection between children and 
adults.
This study also found that adults with HSP ne-
phritis frequently presented with symptoms after 
the initial month of HSP activity, while all such pedi-
atric cases presented within 2 weeks. It has been 
reported that 90% of pediatric HSP nephritis oc-
curred within the first month, while > 40% of adult 
patients presented after the first month of HSP 
disease activity.2 Despite normal urinalysis at the 
onset of disease, extended testing of urine and renal 
function was often necessary for up to 6 months, 
especially in adult patients.1
Renal involvement and complications with renal 
insufficiency were more common in older patients. 
Renal involvement was detected in 20−40% of child-
hood patients,2 but the incidence in adult patients 
varied from 45−85%.14 The risk of disease progres-
sion to a state of renal insufficiency ranged from 
5−15% in children and was approximately 30% in 
adult patients.8 The percentage of patients with 
HSP nephritis that progress to renal failure or end 
stage renal disease has been reported to range 
from 0−19% in children11,15−18 and to be around 
15.8% in adults.11
The risk of renal insufficiency is 12 times higher if 
the initial presentation is complicated by a nephritic 
or nephrotic syndrome, rather than only an abnormal 
urinalysis.1 Half of the patients with renal insuffi-
ciency in this study also presented with nephrotic 
syndrome at the onset of disease. In addition, pedi-
atric patients with renal involvement experienced 
complete recovery. In a retrospective study, Garcia-
Porrua et al showed that the frequency of severe 
renal manifestations in children was significantly less 
than that in adults, and that a complete recovery 
occurred in most cases. In contrast, 19% of adults 
had severe renal manifestations and 13% developed 
renal insufficiency, 10% of them requiring hemodial-
ysis during a 5-year follow-up period.7,8
Patients with abdominal pain as the initial
disease-related symptom had a significantly higher 
probability of developing nephrotic syndrome, and 
persistent rash was a poor prognostic indicator for 
HSP nephritis. In previous studies, persistent rash 
and severe abdominal pain at the onset of HSP 
have been reported to be risk factors for renal 
involvement.8,15,19−22
Poor prognosis associated with HSP nephritis in 
adult patients was also observed in this study; ag-
gressive treatment of these patients may reduce 
the risk of severe renal involvement.20 Management 
of nephritis in HSP is still highly controversial. Be-
sides corticosteroid treatment, various therapeu-
tic modalities have been reported for HSP nephritis, 
such as methylprednisolone pulse therapy,23 uroki-
nase pulse therapy,24 plasma exchange,18 or triple 
therapy consisting of intravenous pulse methylpred-
nisolone, oral cyclophosphamide, dipyridamole and 
prednisolone for rapidly progressive HSP nephri-
tis.25 Adults required high-dose corticosteroids and/
or immunosuppressive drugs more often than chil-
dren. This was most likely related to the higher 
frequency of severe complications in adults with 
HSP.26,27
In conclusion, HSP nephritis in older patients 
had a higher risk of progression to renal insufficiency, 
especially in patients with GI, persistent rash and 
presentation of nephrotic syndrome at the onset 
of disease. Late-onset hematuria was also common 
in adults. More aggressive treatment and extended 
follow-up with repeated urinalysis were therefore 
often necessary in HSP patients with renal involve-
ment, especially adults, despite initially normal renal 
findings.
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